Search clinical trials for: Exjade

Total 47 results

Elliott Vichinsky

Completed

Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload

Iron Overload | Thalassemia

United States
Broncus Technologies

Completed

Exhale (R) Stent for Emphysema

Emphysema

Germany, Australia, Brazil
University Hospital, Grenoble
Novartis

Recruiting

Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents (LODEFI)

Myelodysplasia

France
Novartis Pharmaceuticals

Completed

Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food

Transfusional Hemosiderosis

United States
Wolfson Medical Center
Hadassah Medical Organization; Tel-Aviv Sourasky Medical Center; Sheba Medical... and other collaborators

Completed

Evaluation the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load

Myelodysplastic Syndrome

Israel
Fondazione Italiana Sindromi Mielodisplastiche-ETS

Terminated

Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS

Myelodysplastic Syndromes

Italy
Assistance Publique - Hôpitaux de Paris
Association pour l'Etude des Fonctions Digestives (AEFD)

Unknown

Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda

Porphyria Cutanea Tarda

France
University of Texas Southwestern Medical Center
Novartis Pharmaceuticals

Completed

Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda

Porphyria Cutanea Tarda

United States
Novartis Pharmaceuticals

Completed

Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration) (ESCALATOR)

Iron Overload | Hemosiderosis | Beta-thalassemia Major | Rare Anemia

Egypt, Oman, Saudi Arabia, Syrian Arab Republic, Lebanon
City of Hope Medical Center

Terminated

Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload

Primary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Iron Overload | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell... and other conditions

United States
Crolll Gmbh
University of Magdeburg; Estimate, GmbH

Completed

The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis (DEFINE)

Non-alcoholic Steatohepatitis | Increased Iron Storage / Disturbed Distribution

Germany
Masonic Cancer Center, University of Minnesota

Terminated

Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Breast Cancer | Iron Overload | Ovarian Cancer | Neuroblastoma | Multiple Myeloma and Plasma Cell Neoplasm

United States
Academisch Medisch Centrum - Universiteit van Amsterdam...

Completed

Low Dose Iron Chelation as TReatment of Oxidative Damage in Sickle Cell Disease (TROS)

Sickle Cell Disease

Netherlands
Abramson Cancer Center of the University of Pennsylvania

Completed

Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)

High Risk MDS or AML Patients

United States
Children's Hospital Los Angeles
Novartis Pharmaceuticals

Terminated

Clinical Importance of Treating Iron Overload in Sickle Cell Disease

Anemia, Sickle Cell | Transfusion Hemosiderosis

United States
Hospices Civils de Lyon

Unknown

Study of the Outcome of Patients With Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Receiving Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (GREFFE)

Myelodysplastic Syndromes | Myeloid Leukemia

France
Haukeland University Hospital
Novartis

Withdrawn

Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome (DefeHEMY)

Myelodysplastic Syndromes | Hemochromatosis

Norway
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Novartis Pharmaceuticals

Terminated

Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome

Anemia | Myelodysplastic Syndrome

United States
University of Erlangen-Nürnberg Medical School
Novartis Pharmaceuticals

Terminated

Exjade-Early-Trial

Myelodysplastic Syndromes

Germany
DisperSol Technologies, LLC

Completed

Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation

Thalassemia Major

Thailand, United States
Broncus Technologies

Unknown

EASE Trial: Exhale Airway Stents for Emphysema (EASE)

Emphysema

United States, Spain, Australia, Canada, Ireland, United Kingdom, Austria, Brazil, Germany, Netherlands
Novartis Pharmaceuticals

Completed

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study (TELESTO)

Myelodysplastic Syndromes

China, Hong Kong, Switzerland, United Kingdom, Italy, Thailand, Bulgaria, Greece, Russian Federation, Canada, Mexico, Australia, Denmark, Malaysia, New Zealand, United States
Asia Diabetes Foundation

Unknown

An Evaluation of the Effectiveness and Acceptability of Delivering Structured Care in Chinese Type 2 Diabetic Patients (JADE-JA)

Diabetes

China
University of Pisa
IRCCS Burlo Garofolo; University of Genova

Recruiting

Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCT

Iron Overload

Italy
Shire

Withdrawn

Treatment of Iron Overload Requiring Chelation Therapy

Metabolic Diseases | Iron Metabolism Disorders | Iron Overload | Beta-thalassemia | Transfusional Hemosiderosis | Transfusional Iron Overload | Iron Chelation
Children's Hospital of Philadelphia
Ann & Robert H Lurie Children's Hospital of Chicago; The Cooley's Anemia Foundation...

Completed

Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia

Thalassemia Major With Severe Transfusional Iron Overload

United States
Weill Medical College of Cornell University

Unknown

Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both

Thalassemia

United States
Sunnybrook Health Sciences Centre
Novartis

Terminated

Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

Canada
Singapore General Hospital
National University Hospital, Singapore

Unknown

Investigating the Safety and Efficacy of the Treatment With the Non-compliant Jade Balloon in TASC C and D Athero-occlusive Infra-inguinal Disease in Patients With Chronic Limb Threatening Limb Ischemia From SingaporE (PINNACLE)

Peripheral Artery Disease | Critical Limb Ischemia

Singapore
Asia Diabetes Foundation

Completed

Establishing a Diabetes Registry Using the JADE-DIAMOND Electronic Portal (CN001) (China-JD)

Diabetes

Hong Kong
Boston Children's Hospital
Novartis

Completed

Pilot Study for Patients With Poor Response to Deferasirox

Sickle Cell Disease | Thalassemia Major | Transfusion-dependent Hemachromatosis

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies

Primary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma and other conditions

United States
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload

Cardiac Iron Overload | Transfusion-dependent β-thalassemia Patients

Greece
Radboud University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development

Completed

Effects of Iron Loading and Iron Chelation Therapy on Innate Immunity During Human Endotoxemia

Anemia | Systemic Inflammatory Process
Asia Diabetes Foundation

Completed

Comparing the Effect of Structured Care Versus Usual Care in Type 2 Diabetes Patients Across the Asia Pacific Region (AP-JD)

Diabetes

Hong Kong
China Medical University Hospital

Completed

Clinical Trial of Deferasirox Combination Treatment With Deferiprone In Thalassaemia Patients

Beta-thalassemia Major
University of California, San Francisco
Spring Wind Herbs

Completed

Treatment of Anal High-grade Squamous Intraepithelial Lesions (HSIL) Through Use of a Chinese Herbal Topical Cream (AIJP)

Anus Neoplasms

United States
Chinese University of Hong Kong
Asia Diabetes Foundation

Completed

Community Health Worker Reduces Care Utilization (JADE-MOS)

Type 2 Diabetes Mellitus

Hong Kong
Lundquist Institute for Biomedical Innovation at...
Novartis; Gilead Sciences; Astellas Pharma Inc

Completed

The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study

Mucormycosis

United States
Groupe Francophone des Myelodysplasies
Novartis

Unknown

A Study of Combined Deferasirox, Vitamin D and Azacytidine in High Risk MDS (GFM-EXVD-AZA)

MDS

France, Belgium
Elizabeth Henry

Terminated

Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65 (EXJADE)

Acute Myeloid Leukemia

United States
Hong Kong Baptist University
The Hong Kong Jockey Club Charities Trust

Completed

The Preventive Effectiveness of the Individualized Jade Wind-Barrier Herbal Tea Bag on the Common Cold in Elderly With Qi-deficiency Constitution (CCJWBT): A Pragmatic Randomized Controlled Trial (CCJWBT)

Common Cold | Preventive Effectiveness | Elderly With Qi-deficiency Constitution | The Individualized Jade Wind-Barrier Herbal Tea Bag | Pragmatic Randomized Controlled Trial

China
Johnson & Johnson Vision Care, Inc.

Completed

Dispensing Evaluation of Subjective Comfort, Vision, and Handling of a New Lens Compared to a Marketed Lens

Refractive Ametropia

United States
Coopervision, Inc.

Completed

Comparative Study to Evaluate the Cosmetic Appearance of Two Brands (Coopervision (CVI) vs. Competitor) of Color Soft Contact Lenses.

Myopia

Mexico
Johnson & Johnson Vision Care, Inc.

Completed

Evaluation of the Performance of Two Contact Lenses Compared to a Marketed Lens

Refractive Ametropia

United States
National Taiwan University Hospital

Completed

The Association of Cigarette Smoking on Exercise Capacity and Skeletal Muscle Function in Taiwan Adult Smokers

Cigarette Smoking

Taiwan
Osijek University Hospital
Josip Juraj Strossmayer University of Osijek

Recruiting

Propofol and Dexmedetomidin vs Midazolam Intraoperative Sedation and POCD (ProDex-POCD)

Postoperative Cognitive Dysfunction | Postoperative Pain, Acute | Pertrochanteric Fracture

Croatia

Search clinical trials for: Exjade

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations